Preclinical development of ALD2510, a Next-Gen Fc-enhanced, TREG-selective and IL-2-sparing anti-CD25 antibody for the treatment of solid tumors

ALD2510 - Alderaan Biotechnology

https://www.abstractsonline.com/pp8/#!/10828/presentation/4033

Jemila Houacine1; Riad Abes1; Anne Marie-Cardine1; Aude Le Roy1; Bettina Serbin1; Lucie Robert2; Jérôme Giustiniani3; Anne-Sophie Chrétien4; Stéphane Fattori4; Laurent Gorvel4; Armand Bensussan5; Daniel Olive4; Arnaud Foussat1

Mar 14, 2023